10x Genomics Balance Sheet
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
10x Genomics financial position
At the end of fiscal 2025, 10x Genomics reported total assets of $1.04 billion, up 13.4% from a year earlier against total liabilities of $245.0 million. Shareholders' equity stood at $796.3 million, or 76.5% of assets. The company held $474.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.46, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
10x Genomics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 473.97M | 344.07M | 359.28M | 219.75M | 587.45M | 663.60M | 424.17M | 65.08M | 47.86M |
| Short-Term Investments | 49.44M | 49.34M | 29.41M | 210.24M | 0 | — | — | — | — |
| Receivables | 47.01M | 87.86M | 114.83M | 104.21M | 85.25M | 51.21M | 33.37M | 28.09M | — |
| Inventory | 56.34M | 83.11M | 73.71M | 81.63M | 59.97M | 29.96M | 15.27M | 8.57M | — |
| Total Current Assets | 684.45M | 584.39M | 596.02M | 635.03M | 747.59M | 774.37M | 480.84M | 106.24M | — |
| Property, Plant & Equipment | 226.71M | 252.65M | 279.57M | 289.33M | 169.49M | 72.84M | 48.82M | 11.13M | — |
| Goodwill | 4.51M | 4.51M | 4.51M | 4.51M | 4.51M | 0 | — | — | — |
| Intangible Assets | 62.33M | 15.67M | 16.62M | 22.86M | 25.40M | 22.35M | 22.37M | 642.00K | — |
| Total Assets | 1.04B | 918.64M | 965.14M | 1.03B | 1.02B | 929.34M | 605.92M | 124.31M | — |
| Accounts Payable | 12.73M | 12.91M | 15.74M | 21.60M | 17.35M | 4.71M | 13.03M | 8.79M | — |
| Short-Term Debt | — | — | — | — | — | 0 | 9.88M | 4.19M | — |
| Total Current Liabilities | 153.45M | 117.63M | 127.16M | 130.96M | 110.36M | 118.13M | 63.05M | 32.36M | — |
| Long-Term Debt | — | — | — | — | — | 0 | 19.84M | 25.49M | — |
| Total Liabilities | 245.04M | 208.50M | 224.10M | 223.24M | 201.26M | 190.27M | 185.84M | 101.05M | — |
| Shareholders' Equity | 796.33M | 710.13M | 741.04M | 805.74M | 817.57M | 739.07M | 420.08M | -219.99M | -112.51M |
| Retained Earnings | -1.51B | -1.47B | -1.28B | -1.03B | -863.32M | -805.10M | -262.37M | -231.12M | — |
| Total Debt | — | — | — | — | — | 0 | 29.72M | 29.68M | — |
| Net Cash (Debt) | 523.41M | 393.40M | 388.69M | 429.98M | 587.45M | 663.60M | 394.45M | 35.40M | 47.86M |
| Shares Outstanding | 127.69M | 122.29M | 119.10M | 115.20M | 112.51M | 108.49M | 96.24M | 14.55M | — |
This table shows 9 annual periods of 10x Genomics's balance sheet, from FY 2025 back to FY 2017, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TXG's reporting calendar. What is a balance sheet?